DARA BioSciences, Inc.
DARA, a specialty pharmaceutical company focused on
oncology and oncology supportive care products, announced today that
it has signed an agreement with Prime Therapeutics Specialty Pharmacy
LLC for distribution of its two lead proprietary products, Gelclair®
(oral bioadhesive gel) for patients with oral mucositis and Soltamox®
(tamoxifen citrate) oral solution to treat breast cancer patients.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in